R&D

Science as our Foundation – for Advancing Technology and Sparking Innovation

Spearheaded by renowned probiotics expert Professor Hsin-Chih Lai, our research has dedicated over 15 years to the research and development of our technology. By integrating advanced research platforms with comprehensive R&D expertise, REVIVEBIO specializes in full-chain development of Next-Generation Probiotics (NGP) and postbiotics.

 

Our approach bridges every stage of innovation—from fundamental scientific discovery to clinical translation—ensuring both precision and efficiency. Through this commitment, REVIVEBIO not only accelerates the application of cutting-edge microbial science but also sparks new possibilities for improving human health and wellbeing.

Our R&D Platforms

With dual R&D bases in Taiwan and Shanghai, we have built a robust multi-faceted validation system:

  • Molecular Biology Research Platform
    Equipped with high-sensitivity molecular detection instruments, mass spectrometry systems and advanced proteomics equipment to profoundly analyze active components and mechanisms of action.
  • Genetic Sequencing Platform
    Established next-generation sequencing (NGS) and whole-genome analysis systems for strain identification, functional prediction and microbiome structural analysis.
  • Cellular Research Platform
    Incorporates immune, neuronal, skin and intestinal epithelial cell models for multi-system functional and safety validation.
  • Application Laboratory
    Equipped for formulation development, stability testing, and small-scale manufacturing, ensuring efficient translation and consistent quality from raw materials to finished products.
  • Preclinical Research Platform
    Designed for nutraceutical and pharmaceutical development, with animal testing facilities and behavioral analysis systems to comprehensively evaluate efficacy in metabolic, immune and neurological disease models.

Our Expertise: Scientific Foundations and Global Collaboration

  • Cross-Disciplinary Integration
    Merging microbiology, immunology, metabolic medicine and aging research to create a multidimensional approach to product development.
  • Regulatory and Patent Expertise
    Experienced with international regulatory processes such as GRAS, Novel Food and FSMP applications. In the process of attaining U.S. FDA GRAS certification for P. Gold RV-01 and actively building a global patent portfolio.
  • Data-Driven Development
    Proprietary probiotic and yeast strain banks, paired with a comprehensive strain database, enable optimized selection and formulation through bioinformatics analysis.
  • Global Research Network
    Collaborations with MIT, Harvard University, Université de Montréal, Xi’an Jiaotong University, and more, with research published in top-tier journals, including Science, Nature Communications, Immunity, and GUT.

The REVIVEBIO team has published over 200 peer-reviewed papers in SCI-indexed journals, covering gut microbiota, immune modulation and inflammation mechanisms. These works have appeared in leading publications such as Nature Medicine, Nature Communications, Nature Reviews Gastroenterology & Hepatology, Trends in Pharmacological Sciences, GUT, and Protein & Cell, underscoring our scientific strength and academic influence in microbial medicine.

 

We believe that precise modulation of the gut microbiome is key to slowing aging and preventing chronic diseases. NGP technology has great potential to influence immune and metabolic pathways, with broad application potential—from improving sarcopenia, regulating gut function, and balancing inflammatory responses in the skin and central nervous system, to addressing circadian rhythm disorders, metabolic syndrome, chronic kidney disease and colorectal cancer.

 

With preclinical research progressing rapidly, REVIVEBIO is actively advancing the clinical translation and product portfolio development of P. Gold RV-01, spanning cosmetic ingredient and products, health supplements, Foods for Special Medical Purposes (FSMP) and even potential new drugs. By combining strong R&D capabilities in Asia with an extensive global collaboration network, we aim to create high-value business models in microbial biotechnology and deliver scientifically validated integrated health solutions for aging societies.